Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 4:50 PM
Ignite Modification Date: 2025-12-25 @ 2:34 PM
NCT ID: NCT01201850
Description: Adverse events that were possibly, probably or definitely related to study therapy were reported.
Frequency Threshold: 5
Time Frame: 16 weeks (duration of trial and 30 days post last dose of bevacizumab)
Study: NCT01201850
Study Brief: The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Bevacizumab (AvastinĀ®) Once enrolled, patients were treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. Bevacizumab (AvastinĀ®): bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. 0 None 0 7 4 7 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Aspartate aminotransferase increased SYSTEMATIC_ASSESSMENT Investigations CTCAE (4.0) View
epistaxis SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders CTCAE (4.0) View
proteinuria SYSTEMATIC_ASSESSMENT Renal and urinary disorders CTCAE (4.0) View
renal and urinary disorders, other SYSTEMATIC_ASSESSMENT Renal and urinary disorders CTCAE (4.0) View
back pain SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders CTCAE (4.0) View
mucositis SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (4.0) View
lymphocyte count decreased SYSTEMATIC_ASSESSMENT Investigations CTCAE (4.0) View
hypophosphatemia SYSTEMATIC_ASSESSMENT Investigations CTCAE (4.0) View
hypomagnesemia SYSTEMATIC_ASSESSMENT Investigations CTCAE (4.0) View